Medibio Enters Into an Agreement with Otsuka Pharmaceutical Development & Commercialization, Inc.
(Thomson Reuters ONE) -
* Medibio will leverage its proprietary Digital Mental Health platform to
process Otsuka clinical data with the goal of further clarifying the role of
biomarker-based, objective measures in management of serious mental illness.
* Paid commercial arrangement for Medibio
SYDNEY, Australia and MINNEAPOLIS, Oct. 08, 2017 (GLOBE NEWSWIRE) -- Medibio
Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), is a mental health
technology company that has pioneered the use of objective biometrics to assist
in the screening, diagnosing, monitoring and management of depression and other
mental health conditions, is pleased to announce it has entered into an
agreement with Otsuka Pharmaceutical Development & Commercialization, Inc.
(Otsuka).
Medibio will apply its advanced proprietary analytic platform to Otsuka clinical
data to characterize key circadian, autonomic, and sleep biomarkers related to
serious mental illness. Under the terms of the agreement, Medibio will receive
payments for services provided.
"We are excited about working with Otsuka, a recognized worldwide leader in
treatments for serious mental illness, to advance our mutual understanding of
the biology that underpins mental illness, with the goal of improving
outcomes," says Medibio CEO and Managing Director Jack Cosentino. "We look
forward to a long and fruitful collaboration."
About Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Company is a global healthcare company with the corporate
philosophy: "Otsuka-people creating new products for better health worldwide."
Otsuka researches, develops, manufactures, and markets innovative products, with
a focus on pharmaceutical products to meet unmet medical needs and nutraceutical
products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health
and also has research programs on several under-addressed diseases including
tuberculosis, a significant global public health issue. These commitments
illustrate how Otsuka is a "big venture" company at heart, applying a youthful
spirit of creativity in everything it does.
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is dedicated
to clinical development of promising drug candidates in mental health, oncology,
cardio-renal, and nephrology. Other activities include strategic planning for
drug approval, marketing, and lifecycle management to maximize a product's full
potential.
OPDC is an indirect subsidiary of Otsuka Pharmaceutical Company, Ltd., which is
a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The
Otsuka group of companies employed 45,000 people worldwide and had consolidated
sales of approximately USD 11 billion in 2016.
All Otsuka stories start by taking the road less travelled. Learn more about
Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and
Twitter at (at)OtsukaUS. Otsuka Pharmaceutical Co., Ltd.'s global website is
accessible at www.otsuka.co.jp/en/.
About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has
pioneered the use of objective biometrics to assist in the screening,
diagnosing, monitoring and management of depression and other mental health
conditions. The company was founded in Australia, with offices located in
Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio
is listed on the Australian Securities Exchange Ltd and trades on the OTCQB
Venture Market www.otcmarkets.comand www.asx.com.au.
+-----------------------------------------------------------------+
| Further Information:Website: www.medibio.com.au |
+--------------------------------+--------------------------------+
| Medibio Shareholder Enquiries: | |
| Jack Cosentino | Australian Media Enquiries: |
| CEO and Managing Director | Peter Taylor |
| Medibio Limited | NWR Communications |
| jack.cosentino(at)medibio.com.au | peter(at)nwrcommunications.com.au |
| T: +1 (952) 465 4787 | T: +61 (0) 412 036 231 |
+--------------------------------+--------------------------------+
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 08.10.2017 - 23:00 Uhr
Sprache: Deutsch
News-ID 562820
Anzahl Zeichen: 5138
contact information:
Town:
Savage
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medibio Enters Into an Agreement with Otsuka Pharmaceutical Development & Commercialization, Inc."
steht unter der journalistisch-redaktionellen Verantwortung von
Medibio Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
